» Articles » PMID: 20546031

Functional Characteristics of N8, a New Recombinant FVIII

Overview
Journal Haemophilia
Specialty Hematology
Date 2010 Jun 16
PMID 20546031
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

  The aim of this study was to evaluate the in vitro function of the new recombinant factor VIII (FVIII) compound, N8. The specific activity of N8 as measured in a FVIII:C one-stage clot assay was 9300±400 IU mg(-1) based on the analysis of seven individual batches. The ratio between the FVIII:C activity measured in clot and chromogenic assays was 1.00 (95% confidence interval 0.97-1.03). N8 bound to von Willebrand factor with Kd values of 0.2 nm when measured by ELISA and by surface plasmon resonance. FVIIIa cofactor activity was determined from the kinetic parameters of factor IXa-catalysed factor X (FX) activation. The rate of activation of N8 by thrombin as well as Km and kcat for FX activation was in the same range as those observed for Advate®. The rate of activated protein C (APC)-catalysed inactivation was similar for activated N8 and Advate®. N8 improved thrombin generation in a dose-dependent manner and induced similar rates of thrombin generation as Advate® and the plasma-derived FVIII product Haemate®. Using thromboelastography (TEG®), N8 was shown to improve the clot formation and clot stability in whole blood from haemophilia A patients. Comparable potency and efficacy of N8 and Advate® was found based on TEG® parameters. Finally, similar binding profiles to immobilized lipoprotein receptor-related protein (LRP) of N8 and Advate® were observed. The study demonstrated that N8 is fully functional in a variety of assays measuring FVIII activity. No functional differences were found between N8 and comparator compounds.

Citing Articles

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.

John M, Chakrabarti P, Apte S, Bhattacharyya M, S C, Hansen T Res Pract Thromb Haemost. 2020; 4(8):1324-1330.

PMID: 33313471 PMC: 7695559. DOI: 10.1002/rth2.12441.


Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.

Gu R, Liu L, Xie L, Gai W, Cao S, Meng Z Acta Pharmacol Sin. 2016; 37(3):408-14.

PMID: 26806305 PMC: 4775845. DOI: 10.1038/aps.2015.121.


Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.

Ahmadian H, Hansen E, Faber J, Sejergaard L, Karlsson J, Bolt G Blood Coagul Fibrinolysis. 2016; 27(5):568-75.

PMID: 26761578 PMC: 4935534. DOI: 10.1097/MBC.0000000000000477.


Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.

Takedani H, Hirose J Drug Des Devel Ther. 2015; 9:1767-72.

PMID: 25848213 PMC: 4378277. DOI: 10.2147/DDDT.S57967.


Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.

Santagostino E, Lentz S, Misgav M, Brand B, Chowdary P, Savic A Haemophilia. 2014; 21(1):34-40.

PMID: 25273984 PMC: 4309503. DOI: 10.1111/hae.12518.